Jennifer J. Knox
About
Jennifer J. Knox is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Jennifer J. Knox has authored 382 papers receiving a total of 17.5k indexed citations (citations by other indexed papers that have themselves been cited), including 206 papers in Pulmonary and Respiratory Medicine, 188 papers in Oncology and 126 papers in Cancer Research. Recurrent topics in Jennifer J. Knox's work include Hepatocellular Carcinoma Treatment and Prognosis (97 papers), Renal cell carcinoma treatment (96 papers) and Cancer Genomics and Diagnostics (92 papers). Jennifer J. Knox is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (97 papers), Renal cell carcinoma treatment (96 papers) and Cancer Genomics and Diagnostics (92 papers). Jennifer J. Knox collaborates with scholars based in Canada, United States and South Korea. Jennifer J. Knox's co-authors include Eitan Amir, Brian I. Rini, Mairéad G. McNamara, Arnoud J. Templeton, Ian F. Tannock, Christian Kollmannsberger, Toni K. Choueiri, Francisco Vera-Badillo, Boštjan Šeruga and Raya Leibowitz‐Amit and has published in prestigious journals such as JAMA, Nucleic Acids Research and Journal of Clinical Investigation.
In The Last Decade
Jennifer J. Knox
368 papers receiving 17.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Jennifer J. Knox Canada | 59 | 8.3k | 7.7k | 4.7k | 4.4k | 4.2k | 382 | 17.5k | ||
| Ho Yeong Lim South Korea | 58 | 5.7k 0.7× | 6.6k 0.9× | 3.5k 0.7× | 3.6k 0.8× | 4.4k 1.1× | 369 | 15.0k | ||
| Marc Ychou France | 59 | 7.7k 0.9× | 16.1k 2.1× | 4.2k 0.9× | 4.8k 1.1× | 2.9k 0.7× | 322 | 22.1k | ||
| Joon Oh Park South Korea | 54 | 7.6k 0.9× | 9.2k 1.2× | 4.5k 1.0× | 4.3k 1.0× | 1.6k 0.4× | 387 | 16.2k | ||
| Jordan Berlin United States | 60 | 6.3k 0.8× | 15.3k 2.0× | 6.6k 1.4× | 3.4k 0.8× | 2.8k 0.7× | 357 | 22.9k | ||
| Valérie Boige France | 63 | 6.2k 0.7× | 9.5k 1.2× | 2.5k 0.5× | 5.7k 1.3× | 3.9k 0.9× | 287 | 17.6k | ||
| Ian Chau United Kingdom | 56 | 7.2k 0.9× | 13.1k 1.7× | 2.6k 0.6× | 5.4k 1.2× | 3.2k 0.8× | 473 | 18.8k | ||
| Yoon‐Koo Kang South Korea | 69 | 13.6k 1.6× | 12.3k 1.6× | 5.2k 1.1× | 6.9k 1.6× | 4.2k 1.0× | 550 | 26.2k | ||
| Alan P. Venook United States | 67 | 3.8k 0.5× | 9.8k 1.3× | 3.1k 0.7× | 3.5k 0.8× | 5.2k 1.2× | 365 | 17.5k | ||
| J. Wanders Netherlands | 38 | 7.9k 1.0× | 11.1k 1.4× | 4.2k 0.9× | 3.0k 0.7× | 1.9k 0.5× | 132 | 19.6k | ||
| Takuji Okusaka Japan | 65 | 4.7k 0.6× | 10.7k 1.4× | 3.4k 0.7× | 6.3k 1.4× | 5.4k 1.3× | 534 | 19.6k |
Countries citing papers authored by Jennifer J. Knox
Since
Specialization
Citations
This map shows the geographic impact of Jennifer J. Knox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer J. Knox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer J. Knox more than expected).
Fields of papers citing papers by Jennifer J. Knox
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Jennifer J. Knox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer J. Knox. The network helps show where Jennifer J. Knox may publish in the future.
Co-authorship network of co-authors of Jennifer J. Knox
This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer J. Knox. A scholar is included among the top collaborators of Jennifer J. Knox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer J. Knox. Jennifer J. Knox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Salvatore, Lisa, Yangqing Deng, Faiyaz Notta, et al.. (2024). GATA6 expression in advanced pancreatic ductal adenocarcinoma (PDAC) as a prognostic and predictive biomarker in the Canadian COMPASS trial and the Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS.. Journal of Clinical Oncology. 42(16_suppl). 4150–4150.
2.
Knox, Jennifer J., Elizabeth M. Jaffee, Grainne M. O’Kane, et al.. (2024). Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.. Journal of Clinical Oncology. 42(17_suppl). LBA4004–LBA4004.
3.
Finn, Richard S., Masatoshi Kudo, Ivan Borbath, et al.. (2024). Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.. Journal of Clinical Oncology. 42(16_suppl). 4100–4100.
4.
Kudo, Masatoshi, Ann‐Lii Cheng, Philippe Merle, et al.. (2024). Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.. Journal of Clinical Oncology. 42(16_suppl). 4109–4109.
5.
Freeman, M. E., Ravi Ramjeesingh, Jessica Li, et al.. (2024). Predictors of short-term death and long-term survival in advanced hepatocellular carcinoma (HCC) treated with contemporary tyrosine kinase inhibitors (TKI) or immunotherapy: A multicenter analysis from the HCC-CHORD consortium.. Journal of Clinical Oncology. 42(16_suppl). 4098–4098.
6.
Fan, Jia, Tanios Bekaii‐Saab, Luca Aldrighetti, et al.. (2024). A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01.. Journal of Clinical Oncology. 42(16_suppl). TPS4199–TPS4199.
7.
Sukrithan, Vineeth, Briant Fruth, Rui Qin, et al.. (2023). A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocrine Related Cancer. 30(11).
8.
Freeman, M. E., Conor O’Donnell, Brandon M. Meyers, et al.. (2023). Real-world multicentre analysis of patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (A+B): Efficacy, esophagogastroduodenoscopy (EGD) uptake and bleeding complications.. Journal of Clinical Oncology. 41(16_suppl). 4105–4105.
9.
Knox, Jennifer J., et al.. (2023). PD-4 Deep learning of pancreatic cancer histopathology images predicts recurrence after surgery. Annals of Oncology. 34. S2–S2.
10.
Doherty, Mark, Vincent C. Tam, Mairéad G. McNamara, et al.. (2022). Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer. British Journal of Cancer. 127(8). 1473–1478.
11.
McNamara, Mairéad G., Lipika Goyal, Mark Doherty, et al.. (2020). NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncology. 16(16). 1069–1081.
12.
Farahvash, Armin, Jennifer J. Knox, & Jonathan A. Micieli. (2020). Severe optic neuropathy as the presenting sign of leptomeningeal carcinomatosis from pancreatic cancer. Canadian Journal of Ophthalmology. 55(6). e207–e209.
13.
McNamara, Mairéad G., Andre Lopes, Harpreet Wasan, et al.. (2020). Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. Journal of Hepatology. 73(5). 1109–1117.
14.
Finn, Richard S., Baek‐Yeol Ryoo, Philippe Merle, et al.. (2019). Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 38(3). 193–202.
15.
Mian, M. Firoz, Mairéad G. McNamara, Mark Doherty, et al.. (2016). Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers. Journal of Clinical Pathology. 69(8). 695–701.
16.
Jewett, Michael A.S., et al.. (2013). Canadian Kidney Cancer Forum 2008. Canadian Urological Association Journal. 2(3). 183–183.
17.
Xu, Junyao, Jennifer J. Knox, Emin Ibrahimov, et al.. (2012). Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer. Clinical Cancer Research. 19(1). 118–127.
18.
Horgan, Anne M., Natasha B. Leighl, Linda Coate, et al.. (2011). Impact and Feasibility of a Comprehensive Geriatric Assessment in the Oncology Setting. American Journal of Clinical Oncology. 35(4). 322–328.
19.
Knox, Jennifer J., Rebecca Wong, A. Visbal, et al.. (2010). Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer. 116(17). 4023–4032.
20.
Zama, Ivan, Thomas E. Hutson, Paul Elson, et al.. (2010). Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer. 116(23). 5400–5406.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ho Yeong Lim Breakdown of academic impact, for papers by Marc Ychou Breakdown of academic impact, for papers by Joon Oh Park Breakdown of academic impact, for papers by Jordan Berlin Breakdown of academic impact, for papers by Valérie Boige Breakdown of academic impact, for papers by Ian Chau Breakdown of academic impact, for papers by Yoon‐Koo Kang Breakdown of academic impact, for papers by Alan P. Venook Breakdown of academic impact, for papers by J. Wanders Breakdown of academic impact, for papers by Takuji Okusaka